Investing.com - Regeneron Pharma (NASDAQ:REGN) reported second quarter earnings that beat analysts' expectations on Tuesday and revenue that topped forecasts.
The firm reported earnings per share of $6.02 on revenue of $1.93B. Analysts polled by Investing.com expected EPS of $5.37 on revenue of $1.8B. That compared to EPS of $5.45 on revenue of $1.61B in the same period a year earlier. The company had reported EPS of $4.45 on revenue of $1.71B in the previous quarter.
For the year, Regeneron Pharma shares are down 19.79%, under-performing the Nasdaq which is up 18.74% year to date.
Regeneron Pharma follows other major Healthcare sector earnings this month
On Tuesday, July 16, 2019, J&J reported second quarter EPS of $2.58 on revenue of $20.56B, compared to forecasts of EPS of $2.46 on revenue of $20.29B.
Merck&Co earnings beat analyst's expectations on Tuesday, July 30, 2019, with second quarter EPS of $1.3 on revenue of $11.76B. Investing.com analysts expected EPS of $1.16 on revenue of $10.96B
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar